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Background
Crohn’s disease (CD) is one of the two main forms of 
inflammatory  bowel  disease  (IBD),  the  other  being 
ulcera  tive  colitis  (UC).  It  is  a  chronic  disease  charac­
terized  by  recurring  inflammation  of  the  gut,  and  is 
thought  to  arise  in  response  to  the  commensal 
microflora  in  a  genetically  susceptible  host  [1].  It  can 
affect the entire gastrointestinal tract, although the most 
common locations are the terminal ileum and the colon. 
Symptoms can be diffuse, and include (bloody) diarrhea, 
abdominal  discomfort,  weight  loss  and  anemia,  and 
there  may  also  be  extra­intestinal  symptoms  such  as 
arthritis, and eye and skin disorders. Complications such 
as  strictures  often  occur  in  CD,  and  since  the 
inflammation  is  trans  mural,  fistulas  and  abscesses  can 
develop, and these eventually require surgical treatment 
[2]. Most of the medications have significant side effects, 
and they are expensive, and often ineffective. CD is a 
major burden on healthcare services, with a prevalence 
of 100 to 150 cases per 100,000 persons per year in the 
western world and with a peak age of onset between 10 
and 30 years of age [3]. CD is partly heritable; this is 
reflected in the higher concordance rate in monozygotic 
twins compared with dizygotic twins. The concordance 
for CD in dizygotic twins is 4%, and for monozygotic 
twins it is as high as 56% [4].
Prior to the introduction of genome­wide association 
studies (GWASs), only a few genetic factors (for example, 
NOD2, which encodes nucleotide binding oligomeriza­
tion domain 2) had unequivocally been associated with 
CD.  However,  multiple  GWASs  have  now  been  per­
formed for CD, and a recent meta­analysis carried out by 
Franke  et  al.  [5]  has  unveiled  71  genetic  variants  as 
associated with CD; Table 1 highlights some noteworthy 
genes  from  that  study.  Many  of  the  genes  cluster  in 
several different molecular pathways and gene networks. 
In  particular,  results  from  GWASs  have  indicated  the 
importance  of  the  immune  system  in  disease  patho­
genesis by identifying genes involved in innate and adap­
tive immunity. Hence, the association of IRGM, encoding 
immunity­related  GTPase  family  M,  and  ATG16L1, 
encoding  autophagy­related  16­like  1,  with  CD  has 
implicated the process of autophagy [6]. The association 
of NOD2, CARD9, which encodes caspase recruitment 
domain family member 9, and TLR4, which encodes Toll­
like  receptor  4,  indicates  the  involvement  of  pattern 
recognition  mechanisms  of  the  innate  immune  system 
[7]. Other genes are involved in pro­inflammatory path­
ways (T helper 1 cells and T helper 17 cells) and in anti­
inflammatory  pathways  (regulatory  T  cells  and  IL­10), 
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pathogenesis (Figure 1) [8]. Another interesting association 
mapped to the FUT2 gene, which encodes secretor type 
fucosyltransferase  and  regulates  secretion  of  A  and  B 
blood  group  antigens  in  intestinal  mucosa  [9].  Recent 
functional  studies  have  suggested  that  fucosylation  of 
mucin proteins is involved in interception and exclusion 
of  bacteria;  thus,  association  of  FUT2  with  CD  might 
imply  a  role  for  the  functional  state  of  mucin  in  CD 
patho  genesis  [10].  Although  5  years  of  GWASs  have 
Table 1. Notable genes within regions associated with Crohn’s disease
Gene	 Odds	ratio	(95%	CI)	 Function
Innate immunity   
	 NOD2 (nucleotide binding oligomerization domain 2)  2.2-4.0 [58]  Involved in pattern recognition
	 ATG16L1 (ATG16 autophagy related 16-like 1)  1.34 (1.29-1.40) [5]  Involved in autophagy
	 IRGM (immunity-related GTPase family, M)  1.37 (1.28-1.47) [5]  Involved in autophagy
	 TLR4 (Toll-like receptor 4)  1.29 (1.08-1.54) [59]  Involved in pattern recognition
	 CARD9 (caspase recruitment domain family, member 9)  1.18 (1.13-1.22) [5]  Involved in pattern recognition
	 VAMP3 (vesicle-associated membrane protein 3)  1.05 (1.01-1.10) [5]  Involved in autophagy and TNF-α metabolism
	 REL (reticuloendotheliosis viral oncogene homolog)  1.14 (1.09-1.19) [5]  Transcriptional activator of NF-кB
	 ERAP2 (endoplasmic reticulum aminopeptidase 2)  1.05 (1.02-1.09) [5]  Involved in peptide trimming upon NF-кB stimulation; required for 
      the generation of HLA binding peptides
	 UBE2L3 (ubiquitin-conjugating enzyme E2L 3)  0.70 [15]  Ubiquitinates, among others, the NF-кB precursor
Adaptive immunity   
	 IL23R	(IL-23 receptor)  2.66 (2.36-3.00) [5]  Activates Th17 cells
	 IL12B (IL-12β)  1.18 (1.13-1.24) [5]  Stimulates Th0 differentiation to Th1 cells
	 CCR6 (chemokine (C-C motif) receptor 6)  1.17 (1.12-1.22) [5]  Chemoattractant receptor of immune cells
	 HLA-DQA2 (major histocompatibility complex, class II,   1.19 (1.13-1.25) [5]  Antigen presenting to Th0
  DQα2)
	 TNFSF11 (tumor necrosis factor super family 11)  1.10 (1.05-1.15) [5]  Augments the ability of dendritic cells to stimulate naive T-cell 
      proliferation
	 TNFSF15 (tumor necrosis factor super family 15)  1.21 (1.15-1.27) [5]  Mediates activation of NF-кB
	 ICOSLG	(inducible T-cell co-stimulator ligand)  1.18 (1.13-1.23) [5]  Acts as a co-stimulatory signal for T-cell proliferation and 
      cytokine secretion
	 IL2RA (IL receptor α)  1.11 (1.05-1.16) [5]  Th0 activation
	 TAGAP (T-cell activation GTPase-activating protein)  1.10 (1.05-1.14) [5]  May function as a GTPase activating protein and may play 
      important roles during T-cell activation
	 IL10 (IL-10)  1.12 (1.07-1.17) [5]  Inhibits synthesis of pro-inflammatory cytokines
	 IL18RAP (IL-18 receptor accessory protein)  1.19 (1.14-1.26) [5]  Protein required for NF-кB activation 
	 TYK2	(tyrosine kinase 2)  1.12 (1.06-1.19) [5]  Probably involved in intracellular signal transduction by 
      initiation of IFN signaling
	 JAK2 (Janus kinase 2)  1.18 (1.13-1.23) [5]  Involved in JAK/STAT pathway; mediates signal transduction 
      of many cytokines
	 STAT3	(signal transducer and activator of transcription 3)  1.15 (1.10-1.21) [5]  Involved in JAK/STAT pathway; mediates signal transduction 
      of many cytokines
	 SMAD3	(SMAD family member 3)  1.12 (1.07-1.16) [5]  Involved in Treg activation through TGF-β signal transduction
	 ICAM1,3 (intercellular adhesion molecule)   1.12 (1.06-1.19) [5]  Homing of leukocytes to inflammation
Other genes of interest   
	 MUC1,19 (mucin)   1.74 (1.55-1.95) [5]  Involved in mucus production, to protect the epithelial barrier 
	 FUT2 (fucosyltransferase 2)  1.07 (1.04-1.11) [5]  Involved in the A and B antigen synthesis pathway
	 PUS10 (pseudouridylate synthase 10)  1.16 [19]  Post-transcriptional nucleotide modification of structural RNAs, 
      including tRNA, rRNA and sRNAs
Genes that we consider to be noteworthy in the Crohn’s disease associated loci. Further investigation is necessary to identify the causal variants. CI, confidence 
interval; HLA, human leukocyte antigen; IFN, interferon; IL, interleukin; JAK, Janus kinase; NF, nuclear factor; rRNA, ribosomal RNA; sRNA, splicing RNA; STAT, signal 
transducer and activator of transcription; TGF, transforming growth factor; Th, T helper cell; TNF, tumor necrosis factor; Treg, regulatory T cell; tRNA transferRNA.
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as much as 77% of the estimated heritability for CD is still 
considered to be unexplained [5].
Thus, one of the current challenges in the study of CD, 
like  other  complex  diseases,  is  to  identify  potential 
sources  of  this  hidden  heritability.  These  might  be 
additional common variants with very limited effect size, 
or  rare  variants  with  a  higher  effect  size.  Part  of  the 
hidden heritability may lie in structural variations such as 
copy number variations (CNVs; a type of structural DNA 
sequence  alteration,  including  deletions,  duplications, 
insertions and inversions, that results in varying numbers 
of copies of a particular gene or DNA sequence from one 
person to the next) or even more complicated mecha­
nisms,  such  as  epistatic,  gene­environment  and  epi­
genetic interactions.
In  this  review,  we  discuss  the  known  genetic  risk 
factors  for  CD,  the  potential  sources  of  the  hidden 
heritability, and strategies to investigate these.
Further exploration of GWAS results
Thus far, the GWASs performed for CD have implicated 
many genes, and have thereby provided valuable insights 
into the etiology of CD. However, there are several ways 
to explore GWAS results in more depth that might lead 
to solving a part of the hidden heritability puzzle. The 
design of GWASs holds several limitations, with the first 
being  the  extensive  correction  needed  for  multiple 
testing. Hence, many true­positive findings are discarded 
because of the stringent significance thresholds, and large 
amounts of data are therefore ignored. Several methods 
have been applied successfully to overcome this statistical 
power issue. A major step to overcoming this problem 
has been taken by the International IBD Genetics Con­
sortium  (IIBDGC)  [11],  which  performed  a  novel 
meta­analysis of six index GWASs and a follow­up study 
in independent cohorts. This study increased the number 
of  confirmed  CD  loci  to  71,  although  the  explained 
herita  bility only increased from 20% to 23% [5].
Another way to overcome the lack of power inherent in 
GWASs  is  to  follow­up  specific  SNPs  (variation  in  a 
single base in the DNA sequence; the most common type 
of variation in the human genome) identified by them. 
Following up the top 1,000 less­strongly associated loci, 
for  example,  could  yield  new  true  associations.  Meta­
analysis of these results with the results from the index 
GWASs leads to a gain of power, as shown by a study of 
celiac  disease  [12].  Another  approach  is  to  prioritize 
genes from the top associated loci based on interaction 
or functional analyses. This has proven to be a successful 
strategy  in  rheumatoid  arthritis,  where  genes  were 
prioritized  based  on  network  analysis  or  interaction 
analysis [13]. For CD, Wang et al. [14] used a different 
prioritizing criterion based on pathway analysis and they 
uncovered a significant association between susceptibility 
to CD and the IL­12/IL­23 pathway, harboring 20 genes. 
Prioritizing SNPs based on their effect on gene expression 
(for example, expression quantitative trait locus, a locus 
at which genetic allelic variation(s) correlates with varia­
tion in gene expression) led to identification of potentially 
novel associations of CD with UBE2L3, encoding ubiquitin­
conjugating enzyme E2L 3 (involved in ubiquitinating the 
NF­кB precursor), and BCL3, encoding B­cell lymphoma 
3­encoded  protein  (involved  in  downregulation  of  the 
NF­кB pathway) [15].
Results  of  GWASs  and  their  meta­analyses  have 
revealed  that  multiple  autoimmune  diseases  have  a 
common genetic architecture [16]. Several studies have 
been successful in identifying new CD risk variants by 
testing  previously  established  loci  for  other 
Figure	1.	Schematic	representation	of	the	genes	and	pathways	associated	with	Crohn’s	disease	pathogenesis. The ongoing inflammatory 
response in the gastrointestinal tract in patients with Crohn’s disease (CD) is thought to be caused by an aberrant immune response to commensal 
microflora in the gut. In patients with CD, defects in first defense mechanisms (that is, disrupted epithelial and mucosal barrier) contribute to 
increased bacterial penetration (MUC1 and MUC19). Genes involved in pattern recognition (NOD2,	TLR4	and CARD9) suggest an increased response 
of antigen-presenting cells to commensal microbes. Consequently, the NF-кB cascade is activated (TNFSF15), leading to production of pro-
inflammatory cytokines. Association of REL and UBE2L3	suggest an impaired NF-кB negative feedback. Antigen-presenting cells migrate to Peyer’s 
patches (intestinal mesenteric lymph nodes) (TNFSF11) to present antigens and stimulate T-cell proliferation (IL2RA	and TAGAP) and differentiation. 
T cells of patients with CD, in turn, respond more intensely. Th0 cells are stimulated to differentiate into T-cell subtypes regulated by a variety of the 
produced cytokines and their receptors. Th17 cells are involved in many immune-related diseases, and they are activated through IL-23R, which, 
in turn, activates the JAK-STAT-TYK (Janus kinase-signal transducer and activator of transcription-tyrosine kinase) pathway that enhances pro-
inflammatory cytokine production (JAK2,	STAT3 and	TYK2). Th1 and Th17 cells are pro-inflammatory, whereas Treg cells downregulate the immune 
response. Another major contribution to CD pathogenesis comes from autophagy. In autophagosomes, intracellular components, including 
phagocytosed microbes, are degraded, after which their antigens are presented to CD4+ cells. Autophagy is at least partly regulated by the CD risk 
genes ATG16L1, IRGM and VAMP3. The activation of CD4+ cells leads to the production of pro-inflammatory cytokines and the maintenance of the 
inflammation. All the displayed processes could finally lead to homing of leukocytes to inflammation sites (ICAM1,3, CCR	cluster), and neutrophil 
recruitment. Consequently, chronic inflammation, ulceration and deeper microbial penetrance occur. The known associated genes are shown 
in red. Table 1 summarizes the associated loci shown here. CCL20, chemokine (C-C motif) ligand 20; ICOS, inducible T-cell co-stimulator; MDP, 
muramyl dipeptide; NF, nuclear factor; TCR, T-cell receptor; TGF, transforming growth factor; TGFBR, TGF β receptor; Th, T helper cell; TNF, tumor 
necrosis factor; Treg, regulatory T cell.
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developed a new method to identify shared risk loci of 
two immune­mediated diseases with a partially shared 
genetic back  ground, namely celiac disease and CD. To 
increase  the  statistical  power,  they  performed  a 
combined analysis of GWAS results from celiac disease 
and  CD,  and  identified  TAGAP,  which  encodes  T­cell 
activation  GTPase­activat  ing  protein,  and  PUS-10, 
which encodes tRNA pseudo  uridylate synthase, as new 
shared loci [19].
The second limitation of the GWAS design is that it 
does  not  lead  to  the  identification  of  causal  variants, 
since  the  tested  SNPs  are  merely  tagging  SNPs  in 
linkage dis  equilibrium (LD; a non­random association 
of  alleles  at  two  or  more  loci  as  a  result  of  a  recent 
mutation,  genetic  drift,  selection,  or  non­random 
mating) with the causal variants. Therefore, the effect 
sizes of known CD loci may be an underestimation of 
their  actual  relative  risk.  To  further  investigate  the 
known risk loci and identify new SNPs, either as causal 
or  close­to­causal  variants,  exten  sive  fine­mapping  is 
currently  being  performed  by  the  IIBDGC  using  a 
custom­made  GWA  chip.  In  addition,  cross­ethnicity 
fine­mapping  has  proven  successful  in  exploring 
conserved haplotype structures (that is, LD blocks) [20]. 
The most common LD blocks occur in all populations; 
however,  their  frequencies  vary  among  different 
ethnicities  [20].  For  example,  common  NOD2  and 
IL23R variants that are well established in Caucasians 
could  not  be  replicated  in  an  Indian  population, 
implying  that  additional  variants  in  these  or  other 
candidate genes may play a role in the pathogenesis of 
CD in Indians [21]. This principle was also successfully 
applied  in  analyzing  the  IL2/IL21  LD  block,  which  is 
strongly  conserved  in  Caucasians  as  opposed  to  Han 
Chinese, in which the IL2 and IL21 genes reside on two 
distinct  LD  blocks.  Both  IL2  and  IL21  could  be 
identified as separate UC risk loci in Han Chinese [22].
Park  et  al.  [23]  proposed  a  method  to  evaluate 
statistical power and risk prediction of future GWASs. 
They estimated that there are, in total, 142 CD suscep­
tibility loci with effect sizes similar to the loci reported 
in  the  current  GWASs,  and  that  a  sample  size  of 
approxi  mately  50,000  would  be  needed  to  uncover 
them.  However,  even  if  a  GWAS  with  hundreds  of 
thousands  of  cases  were  to  provide  new  CD 
susceptibility  loci  and  explain  more  of  the  genetic 
variance, it seems unlikely that it would capture even 
half  of  the  estimated  herita  bility  since  142  loci  only 
explain 20% of the sibling relative risk for CD. We can 
speculate that identification of the true causal variants 
could amplify the effect size for some of the known loci 
and  could  consequently  increase  the  discriminatory 
power of risk models.
Another potential source of hidden heritability could 
lie  in  sample  mix­ups  that  occur  accidentally  during 
sample collection, genotyping or data management. Some 
genetic  variants  influence  gene  expression  pheno  types 
(expression quantitative trait loci); this allows checking 
for concordance between phenotypic measurements and 
genetic variants that affect these phenotypes. Westra et 
al. (personal communication) found that 3% of sample 
mix­ups decrease the number of loci normally discovered 
by 23% for a trait with a heritability of 50% and 500 loci 
explaining  the  total  heritability.  Thus,  sample  mix­ups 
may explain part of the hidden heritability and it will be 
possible to detect them as long as databases encompass 
sufficient  numbers  of  phenotypes  that  are  strongly 
determined by known genetic variants.
GWASs  are  most  likely  to  remain  an  important 
approach for investigating the hidden heritability, since 
the potential of their results can be enhanced by: per­
form  ing meta­analyses (for example, between multiple 
GWASs  or  between  similar  disease  phenotypes); 
following­up  prioritized  SNPs  based  on  pathway, 
functional  or  inter  action  analyses;  studying  SNPs  that 
have  been  associated  with  other  immune­related 
diseases; and expanding the design of GWASs to include 
samples from non­Caucasians.
Low frequency and rare variants
Common variants identified by GWASs represent only 
a  small  fraction  of  the  phenotypic  variation.  Thus, 
much  speculation  about  the  hidden  heritability  has 
focused on the contribution of variants with low allele 
frequencies, defined as 0.5% < minor allele frequency 
(MAF; propor  tion of the less common of two alleles in 
a  population)  <  5%,  or  from  rare  variants  with  MAF 
<0.5%, that are not sufficiently frequent to be captured 
by current GWA arrays, nor sufficiently penetrant to be 
captured  by  traditional,  family­based  linkage  studies 
[24].  Detecting  such  variants  will  be  facilitated  by 
advances in high­throughput sequencing technologies 
and by the wide­ranging catalog of variants with MAF 
>1%  generated  by  the  1000  Genomes  Project  [25]. 
Current efforts to identify rare variants by sequencing 
are  likely  to  focus  on  the  regions  of  most  significant 
GWAS SNPs and around genes already implicated in 
CD  pathogenesis  or  treat  ment.  Resequencing  of 
selected  susceptibility  loci  has  led  recently  to  the 
discovery  of  three  IL23R  (the  gene  en  coding  IL­23 
receptor) coding variants that offer protec  tion against 
CD [26]. The results of this particular study confirmed 
an  increase  in  effect  size  with  decreasing  variant 
frequency, although rare variants explained less of the 
heritability than common variants.
In  addition  to  resequencing  efforts,  whole­genome/
exome sequencing will be needed to detect rare high­risk 
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costs  of  next­generation  sequencing  remain  high,  they 
are dropping fairly rapidly as the technologies improve 
and the process time per sample is becoming shorter; so 
this  method  is  becoming  more  and  more  feasible  and 
accessible  for  researchers.  Evaluating  such  signals  and 
determining the real causal variant will, however, be a 
difficult task. Feng and Zhu [27] developed an alternative 
method  for  searching  for  rare  variants  in  previously 
published GWAS datasets. Their method relies on haplo­
type analysis across the genome and the hypothesis that 
multiple rare variants can be captured by many haplo­
types. Using this method, they confirmed nine previously 
established  loci  and  also  discovered  four  new  CD 
susceptibility loci [27].
Another approach that may prove to be important is 
performing  resequencing  studies  of  individuals  with 
extreme  phenotypes  in  lipid  levels;  these  studies  have 
shown that such individuals seem more likely to be the 
carriers  of  rare,  yet  non­synonymous,  variants  [28].  A 
large number of rare variants may have distinct effects on 
the  phenotype.  Therefore,  pooling  variants  of  similar 
effect and locus­specific matching of cases with specific 
CD subphenotypes and controls throughout the genome 
may help to reveal some of the hidden heritability [29].
Structural variation
It has been estimated that chromosomal rearrangements 
(that  is,  duplications,  deletions,  insertions  and  inver­
sions), collectively named CNVs, comprise 12% of the 
human genome [30]. Currently, more than 15,000 CNV 
loci are catalogued in the Database of Genomic Variants 
[31]. Some CNVs have been linked to complex disorders, 
such  as  autism,  neuroblastoma  and  systematic  lupus 
erythematosus  [32­34].  A  recent  study  suggested  that 
CNVs are enriched in genomic regions containing genes 
that influence immunity [35]. In particular, low and high 
copy numbers of the β­defensin gene (HBD2), which acts 
as an antimicrobial peptide and as a cytokine, have been 
found  to  predispose  to  colonic  CD  [36,37].  Yet,  in  a 
recent study, Aldhous et al. [38] failed to replicate both 
of the previously published associations. Moreover, they 
argued  that  these  two  associations  could  be  due  to 
measure  ment  error  because  of  a  general  deficiency  of 
real­time PCR to distinguish multiple CNV clusters. In 
addition to the β­defensins, a fine­mapping study of the 
IRGM  susceptibility  locus  revealed  a  20­kb  deletion 
polymorphism immediately upstream of IRGM that was 
associated  with  CD  risk  and  IRGM  expression  [39]. 
Further  more,  a  recent  GWAS  of  CNVs  from  the 
Wellcome  Trust  Case  Control  Consortium  has 
confirmed these CNVs for CD, and also discovered new 
CNVs in the IRGM and human leukocyte antigen (5.1 
kb)  regions  [40].  The  Wellcome  Trust  Case  Control 
Consortium study also showed that the most common 
CNVs are well tagged by SNPs in current GWAS chips, 
and that they are unlikely to make much contribution to 
the hidden heritability in common diseases. More work 
is needed to elucidate the functional consequences and 
impact of high copy­number repeats (for example, long 
interspersed  nuclear  elements),  and  of  rare  CNVs  on 
clinical phenotypes, such as CD.
Family-based approaches
Since  the  possibility  of  chip­based  GWASs  became 
available, linkage analysis and family­based approaches 
have  been  largely  discarded.  However,  now  that  the 
opportunities for gene detection by conventional GWASs 
have been almost exhausted, researchers are shifting back 
towards family­based approaches. These approaches can 
be helpful when GWASs fail to detect signals from rare 
variants  and  are  biased  by  population  stratification, 
which  is  defined  as  a  presence  of  subpopulations  in  a 
supposedly  homogeneous  population.  Subpopulations 
arise  from  differences  in  allele  frequencies  between 
individuals as a consequence of distinct ancestral and/or 
demographic  origin.  Family­based  studies  may  also  be 
advantageous since the low frequency risk alleles (SNPs 
with MAF <5%) are likely to be more prevalent in large 
families  with  several  affected  members  and  should 
therefore be easier to detect. By assessing GWAS data in 
such families, large regions of identity­by­descent may be 
identified and found to include genes associated with CD; 
this approach has already proved to be a powerful tool in 
classical linkage analysis. However, the shared environ­
ment of family members is an alternative explanation for 
familial  clustering  that  should  be  taken  into  account. 
Glocker et al. [41] identified loss­of­function mutations 
in two loci by considering early onset colitis as a mono­
genic  trait  in  two  consanguineous  families.  They  per­
formed a genetic linkage analysis followed by candidate 
gene  sequencing  and  identified  the  IL10RA  (the  gene 
encoding  IL­10  receptor  α)  and  IL10RB  (the  gene 
encoding IL­10 receptor β) loci as being associated with 
early­onset enterocolitis. However, it is most likely that in 
this particular case a private variant, not present in the 
general population, is responsible for the disease.
Akolkar  et  al.  [42]  found  that  CD  is  subject  to  a 
parent­of­origin  effect,  indicating  that  loci  affected 
by genomic imprinting play a role in CD pathogenesis. 
In genomic imprinting, the expression of an inherited 
variant is deter  mined by the parent from whom that 
variant  is  inherited.  If  the  maternal  allele,  for 
instance, is inacti  vated by genomic imprinting, then 
expression of the locus is determined by the paternal 
allele only. If this effect is not taken into account, a 
significant loss in the statistical power of the study 
might develop [43].
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for the hidden heritability since low­frequency variants 
accumulate  in  families  with  multiple  affected 
individuals;  moreover,  low­frequency  variants  are  not 
affected  by  popu  lation  stratification  and  they  also 
include  parent­of­origin  effects.  However,  the  causal 
variants  identified  in  such  families  may  prove  to  be 
private variants or the shared environment may play a 
major role.
GWAS aftermath: epistatic, gene-environment and 
epigenetic interactions
Given that a large proportion of the heritability of CD 
and its complex architecture is as yet unexplained, one 
might speculate other aspects of inheritance, such as 
epistasis, gene­environment interactions or epigenetic 
effects,  might  be  involved.  GWASs  may  be  missing 
higher­order genetic effects that arise from the inter­
action of two or more SNPs [44]. The underlying idea 
for such epistatic effects is that a significant proportion 
of the hidden heritability is not due to single common 
variants, nor to single rare variants, but rather to rare 
combinations  of  common  variants.  Since  typical 
GWASs examine the association of single SNPs with a 
phenotype, SNPs that contribute epistatically will not 
be  revealed  by  such  an  analysis.  A  recent  pair­wise 
analysis  of  variants  related  to  the  IL17-IL23  pathway 
showed an increasing odds ratio for CD when the ‘risk’ 
haplotypes  for  these  genes  were  combined  [45]. 
Analysis  of  epistatic  inter  actions  in  better­powered 
datasets, and the use of more efficient computational 
approaches that can account for the complex nature of 
biomolecular  networks,  may  yield  new  genetic  risk 
factors for CD [46,47].
An even more complex source for the hidden herita­
bility might lie in gene­environment interactions, which 
are defined as the joint effect of one or more genes with 
one or more environmental factors that cannot be readily 
explained  by  their  separate  marginal  effects  [48].  The 
strongest and best replicated environmental risk factor 
for  CD  is  smoking,  which  increases  both  the  risk  and 
severity of CD. However, a recent, moderately sized study 
found remarkable differences in associated loci between 
smoking and non­smoking CD patients, thereby implying 
that a complex gene­environment interaction must be at 
work [49]. Another example of the complex interaction 
between genetic and environmental factors was shown in 
a study by Cadwell et al. [50] where Atg16L1-deficient 
mice infected with a specific strain of norovirus developed 
CD­like  phenotypes  in  a  model  of  intestinal  injury 
induced by dextran sodium sulfate. In particular, struc­
tural Paneth cell abnormalities and decreased production 
of  antimicrobial  granules  in  the  mice  resembled  those 
found in CD patients who are homozygous carriers of the 
ATG16L1 risk alleles. Remarkably, the severity of intes­
tinal injury induced by dextran sodium sulfate was not 
only  dependent  on  aberrant  Atg16L1  function  and 
norovirus infection, but also on the timing of infection, 
secretion of the pro­inflammatory cytokines TNF­α and 
IFN­γ,  and  the  presence  of  commensal  bacteria  in  the 
mouse intestine.
Other  environmental  factors,  such  as  appendectomy, 
diet and domestic hygiene habits, may also play a role in 
CD, but the evidence for each of these factors is much 
weaker.  To  study  gene­environment  interactions  will 
require careful consideration of the epidemiologic study 
design,  exposure  assessment,  and  methods  of  analysis, 
paying particular attention to ways of harmonizing these 
features across consortia.
An additional source of the hidden heritability might 
not  lie  in  the  genome  sequence  itself,  but  in  subtle 
mechanisms interfering with genome functions, such as 
gene  expression.  These  mechanisms  include  histone 
modification,  methylation  and  gene  inactivation,  and 
are covered by the study of epigenetics. However, there 
is much controversy on this topic. Its role in CD is un­
known, but there are some hints that methylation plays 
a  role  in  other  complex  diseases:  type  2  diabetes, 
rheuma  toid  arthritis  and  neurodegenerative  diseases 
[51­53]. Epigenetics is also correlated with age, gender 
and  nutri  tion,  and  it  is  likely  that  there  are  other 
environmental factors to be discovered [54,55]. It has 
been shown that changes in DNA methylation in mice 
can be provoked by dietary alterations and subsequently 
transmitted  across  generations  [56].  Thus,  sequence­
independent epigenetic effects (beyond imprinting) that 
might  be  environ  men  tally  induced  and  transmitted 
across  several  generations  [57]  could  represent  a 
revolutionary glimpse into the enigmatic world of the 
heritability of complex diseases.
Conclusions
CD  is  a  complex  genetic  disorder  with  an  estimated 
heritability of 50% and it is characterized by a recurring 
inflammation of the gastrointestinal tract. Two decades 
of research have led to the discovery of 71 risk loci, which 
have improved our understanding of the disease patho­
genesis. At the moment, approximately 23% of the herita­
bility can be explained. To fully understand the disease 
pathogenesis  and  link  current  insights  to  clinically 
relevant knowledge, it is important to continue our quest 
to identify more genetic risk factors in CD. In this review, 
we  have  presented  various  potential  sources  for  the 
hidden heritability of complex diseases given the current 
knowledge on CD.
It is unlikely that conventional GWASs alone can solve 
the puzzle of the hidden heritability. They are not power­
ful enough to detect signals from common variants with 
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variants with high impact. The resources of GWASs are 
expected to be exhausted fairly soon, although new loci 
have  recently  been  identified  by  replicating  prioritized 
SNPs and meta­analysis of GWAS results.
Identification of causal variants may elucidate a sub­
stantial part of the hidden heritability; however, current 
GWASs  are  insufficient  for  the  purpose  of  identifying 
causal variants since the identified SNPs are merely the 
surrogates  for  causal  variants.  However,  fine­mapping 
can  uncover  SNPs  closer  to  the  causal  variants,  since 
SNPs can then be tested beyond the scope of GWASs. 
The  true  causal  variants  might  be  identified  by  whole 
genome sequencing or exome sequencing. More sources 
than the linear DNA sequence have to be investigated to 
unravel  the  total  heritability.  Epigenetics  and  gene­
environment studies have been shown to be worthwhile, 
but the study of epistatic effects in CD is still needed, 
and results from other complex genetic diseases seem to 
be promising.
To fully unravel the hidden heritability of CD, colla­
bora  tions between genome research centers are crucial, 
since the solutions to identify the hidden heritability are 
either  costly  or  require  a  huge  number  of  cases  and 
controls. The IIBDGC is a good example of what can be 
achieved  by  performing  large  meta­analyses,  and  it  is 
currently  performing  dense  fine­mapping  and 
replication  studies  to  identify  causal  variants  and 
additional risk loci in CD.
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